Meeting
2011 ASCO Annual Meeting
Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181.
Authors
M. Peeters
Antwerp University Hospital, Edegem, Belgium
M. Peeters , T. J. Price , A. H. Strickland , T. E. Ciuleanu , W. Scheithauer , S. O'Reilly , M. M. Keane , D. R. Spigel , Y. Tian , K. Krishnan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00339183
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3574^)
Abstract #
3574^
Poster Bd #
14F
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
A randomized phase II study comparing oral S-1 plus 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC).
First Author: Sotaro Sadahiro
Poster
2011 ASCO Annual Meeting
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS mutated tumors in the randomized German AIO study KRK-0306.
First Author: S. Stintzing
Poster
2019 Gastrointestinal Cancers Symposium
ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
First Author: Zev A. Wainberg
Poster
2018 ASCO Annual Meeting
ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
First Author: Zev A. Wainberg